Introduction {#s1}
============

Mechanotransduction describes processes by which mechanical forces are converted into biological responses. Mechanotransduction is essential for physiological functions including the sense of touch, hearing, and blood pressure regulation. The molecular mechanisms involved in mechanotransduction have been largely unknown, but mechanically activated cation channels are postulated to play important roles ([@bib11]). Piezo1 and Piezo2 are necessary and sufficient for mechanically activated cation channel activity ([@bib8]). These proteins are expressed in various mechanically sensitive cell types, and Piezo1 and Piezo2 have recently been shown to be required for vascular development and touch sensing, respectively ([@bib17]; [@bib19]; [@bib23]; [@bib24]; [@bib27]). In humans, Piezo1 gain-of-function mutations are associated with a hereditary red blood cell condition termed dehydrated hereditary stomatocytosis, while Piezo2 gain-of-function mutations are associated with three phenotypically overlapping conditions termed distal arthrogryposis type 5, Gordon Syndrome, and Marden--Walker Syndrome (Piezo2) ([@bib1]; [@bib2]; [@bib4]; [@bib10]; [@bib20]). Piezo proteins form a distinct class of proteins with no apparent sequence similarity to other proteins and channels ([@bib8]; [@bib3]; [@bib21]). They typically consist of \>2000 amino acids with ∼30--40 putative transmembrane segments, and Piezo1 has been shown to assemble as a homotetramer of ∼1.2 million daltons. Purified Piezo1 can be reconstituted in lipid bilayers resulting in spontaneous cation currents. This indicates that Piezos constitute channel-forming proteins, as opposed to accessory subunits ([@bib9]). Both vertebrate and invertebrate Piezo channels can be activated by mechanical stimuli suggesting an evolutionarily conserved gating mechanism geared to transduce mechanical force ([@bib16]). Indeed, to date, mechanical stimuli are the only means to activate Piezo ion channels. In comparison, temperature-activated transient receptor potential (TRP) ion channels are polymodal and are the sensors of various chemicals that cause a burning sensation such as capsaicin and mustard oil, as well as endogenous compounds that cause inflammation ([@bib15]). Studies on the chemical activation of TRP channels have been crucial to understand the physiological role of these channels and have contributed to mechanistic appreciation of how these ion channels are gated ([@bib14]; [@bib5]; [@bib18]; [@bib7]; [@bib15]). The discovery of a chemical agonist of Piezo channels could thus benefit the study of mechanotransduction.

Results and discussion {#s2}
======================

We set out to probe Piezos for chemical-mediated activation. As Piezos are calcium-permeable channels, we hypothesized that Piezo activity could be monitored using calcium-sensitive fluorophores. We tested this by overexpressing Piezo1 in human embryonic kidney (HEK) cells and monitoring intracellular calcium in response to pressure exerted on the cell via a blunt glass probe. In Piezo1 expressing cells, a sequence of mechanical stimulations using a piezo-electric driven probe caused reversible calcium responses that increased with increasing probe displacement until ultimately an irreversible Ca^2+^ signal ensued as a consequence of membrane rupture. In contrast, control cells showed no reversible responses and only irreversible calcium flux upon cell perforation was observed. ([Figure 1A](#fig1){ref-type="fig"}). This suggested that Piezo1-mediated calcium flux could be measured via calcium fluorophores. With the objective to identify either a Piezo1 or Piezo2 agonist, we co-transfected HEK cells with mPiezo1 and mPiezo2 cDNAs and screened a collection of ∼3.25 million low molecular weight (LMW) compounds for their ability to induce calcium influx in these cells. This led us to identify a synthetic compound that elicits Ca^2+^ flux in Piezo1- but not vector-transfected cells; we named this compound Yoda1 (see 'Materials and methods' and [Figure 1D](#fig1){ref-type="fig"} for screen and Yoda1 details). Yoda1-induced calcium responses depended largely on calcium influx as the chelation of extracellular calcium dramatically reduced the responses, while the depletion of intracellular calcium stores using thapsigargin did not ([Figure 1B](#fig1){ref-type="fig"}). Still, calcium-chelating conditions did not completely abolish the responses, raising the possibility of some functional Piezo1 in intracellular membranes upon overexpression. Concentration-response experiments showed that Yoda1 at micromolar concentrations induced robust Ca^2+^ responses in cells transfected with either human or mouse Piezo1, but not Piezo2-transfected cells, indicating its selectivity for Piezo1 ([Figure 1C](#fig1){ref-type="fig"}). At higher Yoda1 concentrations (\>∼20 μM), the solutions became increasingly opaque. Therefore, the apparent EC~50~ is likely affected by compound insolubility and may not allow meaningful interpretation. We further tested six distinct hPiezo1 mutants that we previously identified in xerocytosis patients and which exhibited increased mechanically induced currents ([@bib1]). Invariably, the Yoda1-induced calcium responses were bigger in cells transfected with these mutant channels than cells transfected with wild-type Piezo1, consistent with their gain-of-function phenotype ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The effect of Yoda1 appears to critically depend on the dichloro substitution ([Figure 1D](#fig1){ref-type="fig"}), as similar compounds present in the collection lacking the chlorines were not identified in the screen (data not shown). Furthermore, the oxidation state of the thioether group appears critical as no activity could be observed with the sulfone analog (tested at ≤30 μM, data not shown).10.7554/eLife.07369.003Figure 1.A high-throughput screen identifies a Piezo1 activating chemical, Yoda1.(**A**) mPiezo1 mediates Ca^2+^ influx upon mechanical activation. Ratiometric Ca^2+^ imaging (Fura-2) of human embryonic kidney (HEK) 293T cells transiently transfected with Piezo1 or untransfected. Cells were subjected to a series of mechanical stimuli, by pressing a glass probe briefly onto the cell surface for 150 ms (arrows). For each consecutive stimulus, the travel distance of probe was increased by 1 μm (**B**) Yoda1 (25 μM) mediates Ca^2+^ responses (384-well FLIPR) in HEK cells transiently transfected with mPiezo1. When indicated, extracellular calcium was chelated by addition of EGTA, or cells were pretreated with thapsigargin to deplete intracellular calcium stores. Traces represent average ± SEM fluorescence of four wells. (**C**) Concentration-response profiles of mouse and human Piezo1 and Piezo2, transfected HEK293T cells assayed using FLIPR suggesting apparent EC~50~ of 17.1 and 26.6 μM for mouse and human Piezo1, respectively (95% confidence interval: 13.4 to 21.9, and 20.6 to 34.4), however, compound (in) solubility precludes meaningful conclusions with respect to EC~50~ (see text). (**D**) Chemical structure of Yoda1. The functional groups tested chlorines and thioether are highlighted.**DOI:** [http://dx.doi.org/10.7554/eLife.07369.003](10.7554/eLife.07369.003)10.7554/eLife.07369.004Figure 1---figure supplement 1.Piezo1 gain-of-function mutations show increased Yoda1 responses.Dose-response curves of HEK293T cells transiently transfected with hPiezo1 and indicated mutants ([@bib1]). Calcium responses were determined in response to increasing concentration of Yoda1 by means of 384-well FLIPR. Average fluorescence change ± SEM in four wells is plotted and fitted to a sigmoidal dose-response curve. Please note that, compared to [Figure 1C](#fig1){ref-type="fig"}, HEK cells here exhibited a more pronounced background response to Yoda1 (see vector control) at higher concentrations. We do not know the cause of such variation in responses.**DOI:** [http://dx.doi.org/10.7554/eLife.07369.004](10.7554/eLife.07369.004)

We next sought to assess the effect of Yoda1 on mPiezo1 channel function directly by recording mPiezo1-mediated currents, both in the presence and absence of mechanical force ([Figure 2A--E](#fig2){ref-type="fig"}). In HEK cells transiently transfected with mPiezo1, using a cell-attached patch configuration, currents were measured before and during a series of increasing negative pressures applied via the recording pipette. The presence of Yoda1 caused multiple distinct effects. Firstly, Yoda1 caused a dramatic change in the kinetics of the mechanical responses, as it notably slowed the inactivation phase of the transient currents ([Figure 2A](#fig2){ref-type="fig"}). Secondly, Yoda1 sensitized mPiezo1 to activation by pressure as indicated by a leftward shift in the current--pressure relationship, reducing the half maximal activation pressure (P50) by about 15 mm Hg ([Figure 2B,C](#fig2){ref-type="fig"}). Lastly, in the absence of negative pressure, we observed small currents in Yoda1-exposed patches. The Yoda1-dependent currents were a fraction of those attained by stretch: 9.0 ± 2.2% of the maximal attainable current compared to 1.5 ± 0.4% in control patches without Yoda1 ([Figure 2B,D,E](#fig2){ref-type="fig"}). These results suggest that Yoda1 both modifies Piezo1 mechanotransduction currents and partially activates Piezo1 in the absence of externally applied pressure (note, however, that some membrane tension exists in cell-attached patches even prior to the application of negative pressure) The partial activation of Piezo1 by Yoda1 might be due to a variety of reasons, including (1) an indirect mechanism of action (but see below), (2) an inefficacious gating mechanism (i.e., acting as a gating modifier instead of a full agonist), or (3) a very high actual EC~50~ (see comment on insolubility above). We also tested the effect of Yoda1 (10 μM) in whole-cell configuration, where mechanical pressure can be applied using a piezoelectric-driven glass probe. This concentration did not lead to measurable mPiezo1 currents in the absence of pressure but did cause a clear slowing of the inactivation phase of the mechanically activated currents, similar to the cell-attached patch experiments ([Figure 2F,G](#fig2){ref-type="fig"}). No such change in kinetics could be observed for Piezo2 consistent with Yoda1 having a Piezo1 selective effect ([Figure 2H](#fig2){ref-type="fig"}).10.7554/eLife.07369.005Figure 2.Yoda1 functions as a gating modifier of Piezo1.(**A**--**E**) mPiezo1-transfected HEK293T cells, cell-attached patch configuration. (**A**) Typical recordings of stretch-activated currents at −80 mV in two mPiezo1-transfected cells with or without 30 μM Yoda1 in the patch pipette. Negative pressure pulses from 0 to −80 mm Hg are applied for 500 ms every 15 s. (**B**) Average normalized current--pressure relationships from mPiezo1-transfected cell recordings with or without 30 μM Yoda1 in the patch pipette (n = 8 and 12, respectively). (**C**) Average P50 values from individual cells used for panel B (p \< 0.05, Mann--Whitney *t*-test). (**D**) High magnification of recording traces shown in panel **A** in the absence of stretch stimulation. Left panels are full-trace histograms. (**E**) Average current without stretch stimulation normalized to maximal stretch-activated current from mPiezo1-transfected cells recorded at −80 mV with or without 30 μM Yoda1 in the patch pipette (n = 8 and 12, respectively; p \< 0.05, Mann--Whitney *t*-test). (**F**--**H**) mPiezo1- and mPiezo2-transfected HEK293T cells, whole-cell configuration. (**F**) Stimulus displacement in 0.5-μm increments every 10 s before (black trace) and 1--2 min after bath application of 10 μM Yoda1 (red trace). A 20-mV step was applied in the beginning of each sweep (sweeps are concatenated and hack marks indicate ∼10 s) to monitor membrane (R~m~) and access (R~a~) resistance. (**G**) The fold change in the inactivation time constant indicates a significant slowing of inactivation during Yoda1 exposure. The effect was completely reversible (not shown). The baseline tau prior to Yoda1 exposure was 16.5 ± 1.5 ms (n = 5) (**H**). No effect was observed upon Yoda1 exposure (up to 5 min) to the mechanically activated currents elicited in a cell expressing mPiezo2. Fold change in inactivation time constant was 0.89-, 1.19-, and 1.25-fold (n = 3). Dotted lines indicated 0 current level (current traces) and displacement at which cell was visibly touched (top). \*p \< 0.005, Mann--Whitney *t*-test.**DOI:** [http://dx.doi.org/10.7554/eLife.07369.005](10.7554/eLife.07369.005)

As discussed above, Yoda1 might act directly on Piezo1 or indirectly via other membrane or even intracellular mediators. To address this, we set out to test its effect on purified mPiezo1 reconstituted in droplet interface lipid bilayers (DIBs). Previously, we reconstituted purified mPiezo1 channels into asymmetric DIBs containing DiPhytanoyl-sn-glycero-3-PhosphoCholine (DPhPC) and 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA) and observed spontaneous cation-selective channel activity ([@bib9]). Here, to study mPiezo1 activation, we utilized symmetric DIBs made up of only DPhPC in which reconstituted mPiezo1 does not show constitutive activity ([Figure 3A](#fig3){ref-type="fig"}). Application of 1 μM Yoda1-induced discernable single-channel currents with a conductance similar to what we previously observed for spontaneously active mPiezo1 in asymmetric bilayers ([Figure 3B](#fig3){ref-type="fig"}). Higher Yoda1 concentrations yielded robust currents with a staircase-like appearance, indicating the presence of multiple (30--40) functional channels ([Figure 3C,D](#fig3){ref-type="fig"}).10.7554/eLife.07369.006Figure 3.Yoda1 activates mPiezo1 in a membrane-delimited fashion.(**A**) Electrical recordings of reconstituted mPiezo1 in the symmetric DiPhytanoyl-sn-glycero-3-PhosphoCholine (DPhPC) bilayers and corresponding all point current histograms without the application of Yoda1. (**B**) Single-channel electrical recordings of reconstituted mPiezo1 in the symmetric DPhPC bilayers in the presence of 1 μM Yoda1. The calculated single-channel conductance of outward currents from the corresponding all point current histograms is 98 ± 9 pS in 0.5 M KCl, 20 mM HEPES, pH 7.4 at V = 100 mV. (**C**) Macroscopic currents of mPiezo1 in the presence of 10 μM Yoda1 (upper left panel) followed by the injection of 30 μM blocker RR (upper right panel). The lower left panel is an expansion of the record (red line) to highlight multiple-channel openings. The lower right panel shows a complete block of channel activity after 6 s of RR injection. (**D**) Maximum current obtained at the indicated concentrations of Yoda1 (red bars) and the subsequent block by RR (black bars). Each concentration point is plotted (red bars) as the function of maximum currents obtained in an 'n' number of experiments at V = 100 mV. Error bars indicate standard deviation. Note the lack of Piezo activity either without Yoda1 (n = 9) or without mPiezo1 (n = 10) in the bilayers. When indicated, Yoda1 is reconstituted in the DPhPC liposomes prior to the bilayer formation. (**E**) Representative histograms of closed (left graph) and open (right graph) dwell times extracted from single-channel analysis of mPiezo1 in the presence of 1 μM Yoda1; τ~1\ closed~ = 3 ± 1 ms, τ~2~ ~closed~ = 57 ± 15 ms, and τ ~open~ = 55 ± 9 ms. (**F**) Representative histograms of closed (left graph) and open (right graph) dwell times extracted from single-channel analysis of mPiezo1 reconstituted in an asymmetric bilayers (without Yoda1); τ~1\ closed~ = 5 ± 1 ms, τ~2~ ~closed~ = 47 ± 9 ms, and τ ~open~ = 13 ± 4 ms.**DOI:** [http://dx.doi.org/10.7554/eLife.07369.006](10.7554/eLife.07369.006)

Next, we assessed single-channel parameters of mPiezo1 reconstituted in symmetric DPhPC bilayers in the presence of 1 μM Yoda1 ([Figure 3E](#fig3){ref-type="fig"}). The channel exhibited closed dwell-time distributions that fitted well to a two-component probability density function; τ~1\ closed~ = 3 ± 1 ms and τ~2~ ~closed~ = 57 ± 15 ms. The two time constants differ in duration by \> 10-fold, a property of a bursting channel, where τ~1\ closed~ is the closed time within a burst, and τ~2\ closed~ is the closed time between bursts. The open dwell time is fitted to a single-component probability density function with characteristic mean open time τ ~open~ = 55 ± 9 ms. Although, no direct comparison can be made for mPiezo1 parameters with and without Yoda1 (due to lack of mPiezo1 activity in symmetric bilayers without Yoda1), we analyzed single-channel properties of mPiezo1 acquired in asymmetric bilayers without Yoda1 ([Figure 3F](#fig3){ref-type="fig"}). In an asymmetric bilayer, the channel exhibited characteristic bursting pattern with two closed time distributions, τ~1\ closed~ = 5 ± 1 ms, τ~2~ ~closed~ = 47 ± 9 ms, and an open time distribution τ ~open~ = 13 ± 4 ms. The significant difference in τ ~open~ (13 ± 4 ms vs 55 ± 9 ms) suggests that mPiezo1 remains open for longer times in the presence of Yoda1. No significant change was observed in τ ~closed~, suggesting that Yoda1 mainly stabilizes the open state rather than destabilizing the closed state.

A detailed biophysical analysis will be required to understand the mechanism of action of Yoda1. Our present analysis provides the first steps towards this goal. For instance, our lipid bilayer experiments suggest that Yoda1 does not require other proteins or specific lipid domains to exert an effect on Piezo1. This suggests its effect is either directly on the channel or via long-range membrane-delimited effects, for instance through a change in membrane tension or curvature of the membrane. Indeed, compounds that modify membrane curvature are known to affect mechanically sensitive ion channels ([@bib22]). However, such compounds are typically amphipaths which Yoda1 is not ([@bib25]). More importantly, the effect of Yoda1 appears governed by stringent structural requirements both on the side of the chemical and on the side of the channel (as no effect on Piezo2 was observed), fitting a model in which Yoda1 directly interacts with Piezo1.

Our electrophysiological experiments in cells suggest that Yoda1 prominently affects the sensitivity and the inactivation kinetics of mechanically induced responses but at best causes a slight mPiezo1 activation in the absence of mechanical stimuli. In the bilayer system, we observed that Yoda1 stabilizes the open channel, potentially explaining the slowing of mPiezo1 inactivation kinetics observed in cells. However, we also observe prominent Yoda1-dependent calcium responses in cell culture and currents in artificial bilayers in the absence of externally applied forces. Therefore, the discrepancy in various levels of channel activity observed with different assays used here remains unexplained, and future in-depth understanding of mechanism of Yoda1 action on Piezo1 might shed light on these apparently disparate observations. Regardless, we show in an accompanying paper that Yoda1 causes Piezo1-dependent red blood cell dehydration, arguing for sufficient activation of the ion channel in the absence of external forces to cause a robust physiological impact.

Irrespective of whether Yoda1 acts as a full activator or as a positive modulator, our results suggest that we have identified the first Piezo1 agonist. This finding is important from two perspectives. Firstly, our studies provide the first evidence of non-mechanical activation of a Piezo channel, suggesting that Piezo1 gating does not exclusively depend on changes in mechanical force. This is important, since it raises the possibility that endogenous agonists of Piezo1 exist which may play an important role in modulating mechanotransduction. Secondly, Yoda1 will provide a valuable tool to facilitate studies aimed at elucidating Piezo1 gating mechanism and exploring its functional significance in various biological processes (see for instance accompanying paper).

Materials and methods {#s3}
=====================

Ratiometric calcium imaging {#s3-1}
---------------------------

### Cell culture and transient transfection {#s3-1-1}

HEK293T cells were grown in Dulbecco\'s modified Eagle\'s medium containing 4.5 mg/ml glucose, 10% fetal bovine serum, 1× antibiotics/antimycotics. Cells were plated onto 12-mm round glass poly-D-lysine coated coverslips placed in 24-well plates and transfected using Fugene6 (Roche, Basel, Switzerland) according to the manufacturer\'s instruction. mPiezo1-IRES GFP was transfected at 250 ng/ml. Cells were tested 2 days post transfection.

Ratiometric imaging was performed essentially as described ([@bib23]). In brief, cells were washed with assay buffer (1× HBSS, 10 mM HEPES, pH7.4) and incubated with 2.5 μM Fura-2 and 0.05% Pluronic F-127 (Life Technologies, Grand Island, NY), in assay buffer for ∼30 min after which cells were washed again with assay buffer and fluorescence was monitored at excitation wavelengths alternating between 340 and 380 nm, using an inverted fluorescence microscope/camera/light source combination. Mechanical pressure was exerted on the cells using a fire-polished glass pipette essentially as described ([@bib8]). The pipette was moved towards the cell at a speed of 1 mm/s.

Fluorescent imaging plate reader {#s3-2}
--------------------------------

### Cell culture and transient transfection {#s3-2-1}

HEK293T cells were grown in Dulbecco\'s modified Eagle\'s medium containing 4.5 mg/ml glucose, 10% fetal bovine serum, 1× antibiotics/antimycotics or penicillin/streptomycin. Cells were seeded in poly-D-lysine coated 384-well plates (1.2 × 10^4^ cells/well) or 1536-well plates (1 × 10^4^ cells/well) and simultaneously transfected using Fugene6 (Promega, Madison, WI) per manufacturer\'s instructions and 62.5 ng cDNA in 40 μl media/well (384 well) or 6.8 ng cDNA in 4 μl media/well (1536 well).

### 384-well format {#s3-2-2}

2 days after transfection, the cells were washed with assay buffer (1× HBSS, 10 mM HEPES, pH7.4) using a ELx405 CW plate washer (BioTek, Winooski, VT). Cells were incubated with assay buffer containing 4 μM Fluo3 and 0.04% Pluronic F-127 (Life Technologies) for ∼60 min and then washed again with assay buffer. Fluorescence was monitored on a fluorescent imaging plate reader (FLIPR) Tetra. To chelate extracellular calcium (1× HBSS contains 1.26 mM CaCl~2~), 2 mM ethylene glycol tetraacetic acid (EGTA) was added to the cells 1 min before addition of the indicated Yoda1 concentration in presence of 2 mM EGTA. To deplete intracellular calcium, 7.5 μM thapsigargin was added 15 min before Yoda1 addition. A 10-mM stock solution of Yoda1 in dimethyl sulfoxide (DMSO) was used resulting in a maximum of 1% DMSO in the assay. Concentration-response curves were fitted using a sigmoidal dose--response at variable slope (GraphPad Prism, La Jolla, CA).

### 1536-well high-throughput screen format {#s3-2-3}

With objective of identifying either a Piezo1 or Piezo2 agonist, we co-transfected cells with mPiezo1 and mPiezo2 cDNA at equal amounts. 2 days after, transfection cells were incubated with Calcium5 (Molecular Devices, Sunnyvale, CA) according to manufacturer\'s instruction and fluorescence was monitored on FLIPR Tetra. About 3.25 million compounds from the LMW Novartis screening library, which includes public domain and proprietary drug-like molecules, were screened at a concentration of 5 μM. Approximately 9000 hits, as defined by 50% activation above DMSO control wells, were selected for retesting in co-transfected cells as well as individual Piezo1 and 2 transfection and control cells. From this, Yoda1 was identified as a potential Piezo1 activator and selected for further study. Yoda1 was obtained from Maybridge Chemical Company.

Cell-attached patch clamp recordings {#s3-3}
------------------------------------

### Cell culture and transient transfection {#s3-3-1}

HEK293T cells were grown in Dulbecco\'s modified Eagle\'s medium containing 4.5 mg/ml glucose, 10% fetal bovine serum, 50 units/ml penicillin, and 50 μg/ml streptomycin. Cells were plated onto 12-mm round glass poly-D-lysine coated coverslips placed in 24-well plates and transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer\'s instruction. mPiezo1-IRES GFP plasmid was transfected at a concentration of 600 ng/ml. Cells were recorded from 12 to 48 hr post transfection.

### Cell-attached patch clamp recordings {#s3-3-2}

Stretch-activated currents were recorded using Axopatch 200B amplifier (Molecular Devices Axopatch 200B). Currents were sampled at 20 kHz and filtered at 2 kHz. External solution used to zero the membrane potential consisted of (in mM) 140 KCl, 1 MgCl~2~, 10 glucose, and 10 HEPES (pH 7.3 with KOH). Recording pipettes were of 2--3 MΩ resistance when filled with standard solution composed of (in mM) 130 NaCl, 5 KCl, 1 CaCl~2~, 1 MgCl~2~, 10 TEA-Cl, and 10 HEPES (pH 7.3 with NaOH). When specified, pipette solution was supplemented with 30 μM Yoda1. Membrane patches were stimulated with 500-ms negative pressure pulses through the recording electrode using Clampex controlled pressure clamp HSPC-1 device (ALA-Scientific, Farmingdale NY). Consecutive sweeps with pressure stimulation ranging from 0 to −80 mm Hg (Δ-10 mm Hg) were applied every 15 s. Full-trace histograms in [Figure 2D](#fig2){ref-type="fig"} were fitted with Gaussian equations using multi-peak fitting analysis of IGOR Pro software.

Whole-cell patch clamp recordings {#s3-4}
---------------------------------

Mechanically activated whole-cell currents at a holding potential of −80 mV were elicited by indentation by a blunt glass probe as described ([@bib8]). Application of vehicle or compounds was achieved by puffer pipette as described ([@bib13]) or bath application; results were similar and combined. Voltage ramp-induced currents were recorded as described ([@bib13]).

### Analysis {#s3-4-1}

The fold change in inactivation time constant (fitted with stimulus vs response with variable slope; GraphPad Prism v6) in the presence of vehicle or compound was determined as described ([@bib12]).

Droplet lipid bilayer recordings {#s3-5}
--------------------------------

### Single-channel recordings using droplet lipid bilayers {#s3-5-1}

Liposomes were made from DPhPC as previously described ([@bib6]; [@bib26]). For reconstitution, the purified protein (protein purified as described \[[@bib9]\]) was diluted ∼200--400-fold into preformed liposomes suspension in 0.5 M KCl, 20 mM HEPES pH 7.4. For Yoda1 containing liposomes, Yoda1 stock of 10 mM was made in DMSO and further diluted to give 1--30 μM final concentration in DPhPC liposomes. The liposomes were extruded through 0.1-mm filter (Avanti Polar Lipids, Alabaster, AL). The protein was added in the Yoda1-containing liposomes prior to the single-channel recordings. All the experiments were performed in 100% DPhPC symmetric bilayers (with and without Yoda1), in 0.5 M KCl to potentiate signal-to-noise ratio. Electrode carrying the proteoliposome droplet was connected to the working end of the amplifier head stage (Molecular Devices Axopatch 200B). The second electrode, in a droplet containing the DPhPC liposomes, was connected to the grounded end of the head stage. In the indicated experiments, RR was injected to a final concentration of 30 μM using a Nano injector (VWR instrument, Sugar Land, TX).

Single-channel acquisition and analysis {#s3-6}
---------------------------------------

Single-channel acquisition and analysis were performed as described previously ([@bib9]). Segments of continuous recordings in the range of 50 s ≤ t ≤ 500 s were used for analysis. The currents were sampled at 20 kHz and filtered at 2 kHz. Additional offline filtering of 1 kHz was applied to the recordings for display. Conductance was determined by fitting a Gaussian curve to the single channel all point current amplitude histograms. Event detection was performed by time-course fitting with the segmental K means (SKM) implemented in QuB software. To avoid the detection of erroneous events, the receiver dead time (*t*~*d*~) was set at 300 μs for all records. Therefore, transitions shorter than *t*~*d*~ were ignored; transitions longer than *t*~*d*~ were accepted as events. Open dwell-time distributions are fitted with a single-component probability density function, whereas closed dwell-time distributions are fitted with a two-component probability density function implemented in QuB. The calculated values are reported as mean ± standard deviation, n denote number of experiments.
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Thank you for sending your work entitled "Chemical activation of the mechanotransduction channel Piezo1" for consideration at *eLife*. Your article has been favorably evaluated by Janet Rossant (Senior editor), a Reviewing editor, and three reviewers. Two of the reviewers, Eric Honoré and Jon Levine, have agreed to share their identity.

The Reviewing editor and the reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission. We are including the three reviews (lightly edited) at the end of this letter, as there are some specific and useful suggestions in them that will not be repeated in the summary here. All of the reviewers were impressed with the importance and novelty of your work.

Reviewer \#1:

In the manuscript "Chemical activation of the mechanotransduction channel Piezo1", the authors report the first chemical agonist (Obi1) of the mechanically activated ion channel Piezo1. The molecule was identified by an unbiased screen of an impressive ∼3 million compound library. The authors use a combination of calcium-imaging, detailed single channel and whole-cell and artificial bilayer electrophysiology to convincingly show that Obi1 is in fact an agonist acting specifically on Piezo1, but not Piezo2.

This finding is important, because it is the first demonstration that this mechanically activated ion channel can also be gated chemically. Due to the astronomical number of screened molecules and the fact that only one hit was identified this molecule is highly unlikely to be identified otherwise and it highlights how unique it is (and probably will be). Having this molecule is significant to study Piezo-related mechanisms and the authors demonstrate this nicely in the accompanying manuscript.

I find this study very impressive and highly interesting. The authors go beyond any reasonable effort in order to convincingly show how Obi1 acts on Piezo1 mechanistically. Thus I have no suggestions for improvements and only a few minor points.

1\) [Figure 3E](#fig3){ref-type="fig"}: It is better to plot the square root of counts instead of counts as this leads to normalization of error bars (although not plotted) in all bins.

2\) The chemical structure of Obi1 should be in the main manuscript and not the supplement and the two functional groups tested (chloridine and thioether) should be highlighted.

Reviewer \#2:

This interesting manuscript reports the discovery of a specific opener for the mechano-sensitive ion channel Piezo1. The Obi1 compound shifts the pressure-effect curve leftward and removes inactivation. Remarkably, this opener works after reconstitution of Piezo1 into an artificial bilayer. Those findings are conceptually important as it demonstrates that this mammalian stretch-activated ion channel can also be opened by an agonist in the absence of mechanical stress. This study also suggests that a natural opener of Piezo1 may possibly exist. I believe that this report is important for a better understanding of cellular mechanotransduction and will certainly be a highly cited paper.

The discovery of the Piezo channels, of their function and pharmacology represent a major step in our understanding of molecular mechanotransduction. I only have a few suggestions which may help to further improve this manuscript. However, those points are optional and I feel that the present paper could be published in its present form.

Minor points and suggestions:

1\) Why does fluorescence goes down in the control cells (pcDNA3.1 + Obi1), as shown in [Figure 1B](#fig1){ref-type="fig"} and [Figure 1C](#fig1){ref-type="fig"}?

2\) There is no basal Piezo1 opening in a reconstituted symmetric bilayer, unlike with asymmetric bilayer as previously reported by the same authors. Can you apply mechanical stress on the symmetric bilayer and now demonstrate that force gates the purified and reconstituted Piezo1?

3\) Is the effect of Obi1 reversed by the peptide GsTMx-4, which is also a gating modifier?

4\) Is the effect of Obi1 mimicked by the anionic amphipathic crenator trinitrophenol? (Although, Obi1 does not work on Piezo2 and a non-specific bilayer effect seems unlikely. Nevertheless, one may imagine that Piezo1 might be more sensitive than Piezo2 to bilayer stress).

5\) In the same line, is the effect of Obi1 reversed by the amphipathic cup-former chlorpromazine?

6\) Of course a key point would be the discovery of natural opener for Piezo1. Any idea?

7\) Please indicate the charge of the molecule at a physiological pH ([Figure 1--figure supplement 1](#fig1s1){ref-type="fig"}).

8\) Can you please cite the review of Nilius-TINS about Piezo1?

9\) Please cite the work of Sachs and collaborators, reporting the modulation of Piezo1 by the gating modifier GsTMx-4?

Reviewer \#3:

The Patapoutian group, that discovered Piezo 1 and 2, have begun the long hard process of drugging these ion channels. In this first manuscript to come from this work, they have successfully isolated a Piezo 1 (and not Piezo 2) agonist, from a library of 2.5 million compounds. Given the rapidity with which the new field of Piezo biology has developed, this compound will be immensely useful to a growing number of investigators interested in the role of Piezo 1 in physiology and pathophysiology.

10.7554/eLife.07369.008

Author response

We thank the reviewers for their constructive input. We address their remarks and concerns below. Initially we named our compound Obi1. However, while our manuscript was in review, a similarly named compound came to our attention (Piezo is not the target of this other OB1). However, to avoid confusion, we have renamed our compound Yoda1.

Reviewer \#1:

*1)* [*Figure 3E*](#fig3){ref-type="fig"}*: It is better to plot the square root of counts instead of counts as this leads to normalization of error bars (although not plotted) in all bins*.

[Figure 3E](#fig3){ref-type="fig"} and [Figure 3F](#fig3){ref-type="fig"} has now been plotted as a square root of counts.

*2) The chemical structure of Obi1 should be in the main manuscript and not the supplement and the two functional groups tested (chloridine and thioether) should be highlighted*.

The chemical structure of the compound Yoda1 is now in the main figure as [Figure 1d](#fig1){ref-type="fig"} and the two functional groups are highlighted.

Reviewer \#2:

*1) Why does fluorescence goes down in the control cells (pcDNA3.1 + Obi1), as shown in* [*Figure 1B*](#fig1){ref-type="fig"} *and* [*Figure 1C*](#fig1){ref-type="fig"}*?*

We observe this effect not only in control cells but also in the Piezo transfected cells when vehicle without Yoda1 is pipetted on the cells. We therefore conclude this as a non-specific effect.

2\) There is no basal Piezo1 opening in a reconstituted symmetric bilayer, unlike with asymmetric bilayer as previously reported by the same authors. Can you apply mechanical stress on the symmetric bilayer and now demonstrate that force gates the purified and reconstituted Piezo1?

We are working on the mechanical activation of reconstituted Piezo1. We believe this to be beyond the scope of the current work.

3\) Is the effect of Obi1 reversed by the peptide GsTMx-4, which is also a gating modifier?

In past experiments we did not observe robust block of Piezo1 mechanoresponses with commercially available GsMTx4. We have to request GsMTx4 from the F. Sachs lab to revisit this at a later time.

*4) Is the effect of Obi1 mimicked by the anionic amphipathic crenator trinitrophenol? (Although, Obi1 does not work on Piezo2 and a non-specific bilayer effect seems unlikely. Nevertheless, one may imagine that Piezo1 might be more sensitive than Piezo2 to bilayer stress)*.

Trinitrophenol (TNP) causes activation of TREK-1 at concentrations of 100-400µM (Patel et al. 1998). Application of 100 or 400µM TNP did not induce Piezo1 specific calcium responses (measured by FLIPR) nor did it block Piezo1 mediated Ca^2+^ responses to 40µM Yoda1 (data not shown).

*5) In the same line*, *is the effect of Obi1 reversed by the amphipathic cup-former chlorpromazine?*

Chlorpromazine (CPZ) at concentrations of 0.1-10 µM was shown to block TREK-1 channels (Patel et al. 1998). Application of 0.1 or 10µM CPZ did not induce Piezo1 specific calcium responses (measured by FLIPR) nor did it block Piezo1 mediated Ca^2+^ responses to 40µM Yoda1 (data not shown).

*6) Of course a key point would be the discovery of natural opener for Piezo1*. *Any idea?*

We hope future investigations may yield insight into this interesting question.

*7) Please indicate the charge of the molecule at a physiological pH (*[*Figure 1--figure supplement 1*](#fig1s1){ref-type="fig"}*)*.

The compound is not charged at neutral pH ([Figure 1D](#fig1){ref-type="fig"}).

8\) Can you please cite the review of Nilius-TINS about Piezo1?

This citation was added.

9\) Please cite the work of Sachs and collaborators, reporting the modulation of Piezo1 by the gating modifier GsTMx-4?

This citation was added.
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